RxDoctor Payments Data

David Busch, DO

Cardiovascular Disease · Garden City, NYNPI 1538288360

Payments from drug & device makers

$3,218in general payments, 2019–2025

Across 199 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$698
  • Impulse Dynamics (USA) Inc.$381
  • Pfizer$185
  • Abiomed$139
  • Janssen Scientific Affairs, LLC$106
  • plus $426 from 12 others

What the payments were for

  • Food & beverage$3,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,218 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$753,316
Medicare patients
1,134
Services billed
5,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban317$393,818
JardianceEmpagliflozin161$223,144
XareltoRivaroxaban90$133,363
EntrestoSacubitril/Valsartan74$107,168
FarxigaDapagliflozin Propanediol74$99,188
MounjaroTirzepatide48$81,357
OzempicSemaglutide29$64,561
Repatha SureclickEvolocumab31$49,870
BrilintaTicagrelor40$35,099
VascepaIcosapent Ethyl26$16,043
Metoprolol Succinate694$12,999
MultaqDronedarone Hcl11$10,205
Valsartan228$6,668
Atorvastatin Calcium592$6,468
Rosuvastatin Calcium260$3,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$393,818317 claims
Boehringer IngelheimJardiance$18$223,144161 claims
Johnson & JohnsonXarelto$45$133,36390 claims
NovartisEntresto$698$107,16874 claims
Lilly USA, LLCMounjaro$31$81,35748 claims
Novo NordiskOzempic$15$64,56129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →